PRESS RELEASES

Webcast
2022 H.C. Wainwright Global Investment Conference
May 24, 2022 7:00 AM EDT

Press Release Archive 1998-2005

Date	Title
May 18, 2022	Cytokinetics and the ALS Association Renew Partnership to Advance the Fight Against ALS	link
May 17, 2022	Cytokinetics to Participate in the 2022 H.C. Wainwright Global Life Sciences Conference	link
May 17, 2022	Cytokinetics Provides Regulatory Update Related to New Drug Application for Omecamtiv Mecarbil	link
May 16, 2022	Cytokinetics Announces Three Upcoming Presentations at the European Society of Cardiology Heart Failure 2022 Congress	link
May 4, 2022	Cytokinetics Reports First Quarter 2022 Financial Results	link
May 3, 2022	Cytokinetics to Hold Annual Meeting of Stockholders	link
April 20, 2022	Cytokinetics to Announce First Quarter Results on May 4, 2022	link
April 8, 2022	Cytokinetics Announces Changes to Board of Directors	link
April 6, 2022	Cytokinetics to Participate in the 21st Annual Needham Virtual Healthcare Conference	link
April 3, 2022	Cytokinetics Announces Results From METEORIC-HF and Additional Data From GALACTIC-HF Presented at the American College of Cardiology 71st Annual Scientific Session	link
April 2, 2022	Cytokinetics Announces Results From Cohort 3 of REDWOOD-HCM Presented at American College of Cardiology 71st Annual Scientific Session	link
April 1, 2022	Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	link
March 24, 2022	Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 71st Annual Scientific Session & Expo	link
March 8, 2022	Cytokinetics to Participate in Upcoming Investor Conferences	link
March 2, 2022	Cytokinetics Announces Cohort 4 of REDWOOD-HCM Is Open to Enrollment	link
March 1, 2022	Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)	link
February 28, 2022	Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day	link
February 24, 2022	Cytokinetics Reports Fourth Quarter 2021 Financial Results	link
February 23, 2022	Cytokinetics Announces Start of SEQUOIA-HCM, a Phase 3 Clinical Trial of Aficamten in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy	link
February 16, 2022	Cytokinetics and the American Heart Association Bay Area Announce a Three-Year Collaboration to Advance Education and Awareness of Heart Disease	link
February 15, 2022	Cytokinetics Announces Topline Results From METEORIC-HF	link
February 10, 2022	Cytokinetics to Announce Fourth Quarter Results on February 24, 2022	link
February 4, 2022	Cytokinetics Announces FDA Acceptance of New Drug Application for Omecamtiv Mecarbil for the Treatment of Heart Failure With Reduced Ejection Fraction	link
February 1, 2022	Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	link
February 1, 2022	Cytokinetics Announces Positive Topline Results from Cohort 3 of REDWOOD-HCM	link
January 24, 2022	Cytokinetics Announces Recipients of Fourth Annual Communications Fellowship Grants	link
January 10, 2022	Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	link
January 7, 2022	Cytokinetics and Royalty Pharma Announce Funding Agreements Totaling up to $450 Million	link
January 3, 2022	Cytokinetics to Participate in the 40th Annual J.P. Morgan Healthcare Conference	link

INVESTORS & MEDIA

PRESS RELEASES

Keyword Search